99669-44-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Aminoethylamino)-pyridine 2 HCL is used as a reagent in the development of various drugs due to its potential application in drug synthesis and its ability to form stable complexes with metal ions.
Used in Chemical Industry:
2-(2-Aminoethylamino)-pyridine 2 HCL is used as a chelating agent for its ability to form stable complexes with metal ions, which makes it valuable in certain chemical processes and applications.
Used in Organic Synthesis:
2-(2-Aminoethylamino)-pyridine 2 HCL is used as a reagent in organic synthesis due to its potential application in the development of various chemical compounds.
Used in Antitumor Activity Research:
2-(2-Aminoethylamino)-pyridine 2 HCL has been investigated for its potential antitumor activity, making it a promising candidate for further research and development in the field of oncology.
Used in Metal Catalysts for Chemical Reactions:
2-(2-Aminoethylamino)-pyridine 2 HCL has been studied as a potential ligand for metal catalysts in chemical reactions, which could enhance the efficiency and selectivity of certain chemical processes.

InChI:InChI=1/C7H11N3.2ClH/c8-4-6-10-7-3-1-2-5-9-7;;/h1-3,5H,4,6,8H2,(H,9,10);2*1H

Upstream product

• 109-09-1 2-chloropyridine 
• 107-15-3 ethylenediamine 
• 187339-12-4 2-[[2-(Boc-amino)ethyl]amino]pyridine-N-oxide 
• 187339-13-5 [2-(Pyridin-2-ylamino)-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Vitronectin receptor antagonists

PCT No. PCT/US98/00490 Sec. 371 Date Jun. 29, 1999 Sec. 102(e) Date Jun. 29, 1999 PCT Filed Jan. 8, 1998 PCT Pub. No. WO98/30542 PCT Pub. Date Jul. 16, 1998This invention relates to certain tricyclic compounds that are integrin receptor antagonists.

Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics

A peptide RGD analog containing a novel 2-aminopyridine arginine mimetic was discovered to have good affinity and selectivity for the vitronectin receptor. Incorporation of the 2-aminopyridine arginine mimetic into the 3- oxo-1,4-benzodiazepine-2-acetic acid integrin antagonist series led to novel and potent nonpeptide vitronectin receptor antagonists with promising levels of oral bioavailability.

Integrin receptor antagonists

Compounds of formula (I) STR1 wherein A1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R3 or R4 ; X1 --X2 is CHR1 --CH, CR1 =CH, NR1 --CH, S(O)u --CH or O--CH; X3 is CR5 R5 ', NR5, S(O)u or O; R2 is --OR', --NR'R", --NR'SO2 R'", --NR'OR', --OCR'2 C(O)OR', --OCR'2 OC(O)--R', --OCR'2 C(O)NR'2, CF3 or --COCR'2 R2 '; R3, R4 and R7 are independently H, halo, --OR12, --SR12, --CN, --NR'R12, --NO2, --CF3, CF3 S(O)r --, --CO2 R', --CONR'2, R14 --C0-6 alky-, R14 --C1-6 oxoalkyl-, R14 --C2-6 alkenyl-, R14 --C2-6 alkynyl-, R14 --C0-6 alkyloxy-, R14 --C0-6 alkylamino- or R14 --C0-6 alkyl--S(O)r --; R6 is W--(CR'2)q --Z--(CR'R10)--U--(CR'2)s --V-- or W'--(CR'2)q --U--(CR'2)s -- U and V are absent or CO, CR'2, C(=CR152), S(O)n, O, NR15, CR15 'OR15, CR'(OR")CR'2, CR'2 CR'(OR") C(O)CR'2, CR152 C(O), CONR15, NR15 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR15, NR15 C(S), SO2 NR15, NR15 SO2, N=N, NR15 NR15, NR15 CR152, NR15 CR152, CR152 O, OCR152, C$(m)ZC, CR15 =CR15, Het, or Ar, provided that U and V are not simultaneously absent, and W and W' are a nitrogen-containing substituent, and integrin receptor antagonists.

Synthesis of Fluorescent Amino Acids and Peptides with 2-Aminopyridine at the Carboxyl or Amino Terminus

N-(2-Pyridyl) derivatives of glycine (1), DL-alanine (2), DL-valine (3), and DL-norleucine (4) were synthesized as fluorescence labeled amino acids.These amino acids were used for the synthesis of N-terminal fluorescence-labeled peptides.N-(2-Pyridyl)-1,2